Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes

Pediatric Diabetes

Volumn 16, Issue 3, 2015, Pages 164-176

  Thalange, Nandu ^a   Deeb, Larry ^b   Iotova, Violeta ^c   Kawamura, Tomoyuki ^d   Klingensmith, Georgeanna ^e   Philotheou, Areti ^f   Silverstein, Janet ^g   Tumini, Stefano ^h   Ocampo Francisco, Ann Marie ⁱ   Kinduryte, Ona ⁱ   Danne, Thomas ^j  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b Larry Deeb PA   (United States)

^c UNIVERSITY HOSPITAL ST MARINA   (Bulgaria)

^d Osaka Prefecture University   (Japan)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Groote Schuur Hospital and UCT Private Academic Hospital   (South Africa)

^g UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^h Ospedale Clinicizzato SS Annunziata   (Italy)

ⁱ NOVO NORDISK A S   (Denmark)

^j Children's Hospital Auf der Bult   (Germany)

more..

Author keywords

Adolescents; Children; Insulin degludec; Type 1 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DETEMIR; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LONG ACTING INSULIN;

ADOLESCENT; ARTICLE; BOLUS INJECTION; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFANT; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INJECTION PEN; KETOACIDOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 1; DIABETIC KETOACIDOSIS; METABOLISM; PRESCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; DIABETIC KETOACIDOSIS; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INFANT; INSULIN ASPART; INSULIN DETEMIR; INSULIN, LONG-ACTING;

EID: 84926218961     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12263     Document Type: Article

References (38)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med 1993: 329: 979-986.
2. The Diabetes Control and Complications Trial Research Group. Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. Diabetes Care 1995: 18: 1415-1427.
3. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000: 342: 381-389.
4. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002: 287: 2563-2569.
5. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005: 353: 2643-2653.
6. Halvorson M, Yasuda P, Carpenter S, Kaiserman K. Unique challenges for paediatric patients with diabetes. Diabetes Spectr 2005: 18: 167-173.
7. Rewers M, Pihoker C, Donaghue K, Hanas R, Swift P, Klingensmith GJ. ISPAD Clinical Practice Consensus Guidelines 2014 Compendium. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes 2014: 15 (Suppl. 20): 102-114.
8. Chiang JL, Kirkman MS, Laffel LM, Peters AL. Type 1 diabetes sourcebook authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 2014: 37: 2034-2054.
9. Desrocher M, Rovet J. Neurocognitive correlation of type 1 diabetes mellitus in childhood. Neuropsychol Dev 2004: 10: 36-52.
10. Clarke W, Jones T, Rewers A, Dunger D, Klingensmith GJ. Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes 2009: 10 (Suppl. 12): 134-145.
11. Wolfsdorf J, ISPAD Clinical Practice Consensus Guidelines 2014 Compendium. Diabetic ketoacidosis in children and adolescents with diabetes. Pediatr Diabetes 2014: 15 (Suppl. 20): 154-179.
12. Morris AD, Boyle DI, McMahon AD, Greene SA, MacDonald TM, Newton RW. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. Diabetes Audit and Research in Tayside Scotland Medicines Monitoring Unit. Lancet 1997: 350: 1505-1510.
13. Rewers A, Chase HP, Mackenzie T et al. Predictors of acute complications in children with type 1 diabetes. JAMA 2002: 287: 2511-2518.
14. ® Summary of product characteristics (available from http://www.medicines.org.uk/emc/medicine/25506)
15. ® Summary of product characteristics (available from http://www.medicines.org.uk/emc/medicine/14584)
16. Heise T, Hovelmann U, Nosek L, Bottcher S, Granhall C, Hahhr H. Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. Diabetes 2011: 60 (Suppl. 1A): LB11 (Abstract).
17. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012: 14: 859-864.
18. Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet 2014: 53: 787-800.
19. Heller S, Buse J, Fisher M et al. Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012: 379: 1489-1497.
20. Meneghini L, Atkin SL, Gough SC et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily. A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care 2013: 36: 858-864.
21. Mathieu C, Hollander P, Miranda-Palma B et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 2013: 98: 1154-1162.
22. World Medical Association Inc. Declaration of Helsinki. Ethical principles for medical research involving human subjects. J Indian Med Assoc 2009: 107: 403-405.
23. ICH Harmonised Tripartite Guideline. Guideline for good clinical practice. J Postgrad Med 2001: 47: 199-203.
24. Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Råstam J. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 2002: 25: 876-882.
25. Mire-Sluis AR, Barrett YC, Devanarayan V et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004: 289: 1-16.
26. Food and Drug Administration. Guidance for Industry: diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. Draft Guidance 2008 Rockville, MD: US Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) [online] (available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071624.pdf). Accessed February 21, 2012.
27. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012: 29: 2104-2114.
28. DeVries JH, Nattrass M, Pieber TR. Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes Metab Res Rev 2007: 23: 441-454.
29. Le Floch JP, Lévy M, Mosnier-Pudar H et al. Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT). Diabetes Care 2009: 32: 32-37.
30. Biester T, Blaesig S, Remus K et al. Insulin degludec's ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes. Pediatr Diabetes 2014: 15: 27-33.
31. American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005: 28: 1245-1249.
32. Garber AJ, King AB, Del Prato S et al. Insulin degludec, an ultralong acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012: 379: 1498-1507.
33. Bode B, Buse JB, Fisher M et al. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN Basal-Bolus Type 1): 2-year results of a randomized clinical trial. Diabet Med 2013: 30: 1293-1297.
34. Davies M, Gross JL, Ono Y et al. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial. Diabetes Obes Metab 2014: 16: 922-930.
35. Davis RE, Morrissey M, Peters JR, Wittrup-Jensen K, Kennedy-Martin T, Currie CJ. Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin 2005: 21: 1477-1483.
36. Frier BM. Hypoglycaemia and cognitive function in diabetes. Int J Clin Pract Suppl 2001: 123: 30-37.
37. Seaquist ER, Anderson J, Childs B et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and The Endocrine Society. J Clin Endocrinol Metab 2013: 98: 1845-1859.
38. ® Summary of product characteristics (available from http://www.medicines.org.uk/emc/medicine/27363/SPC/Tresiba+200+units+mL+Pre-filled+Pen+(FlexTouch)/)